SYSF invites all patients and their caregivers to complete this survey on Libtayo/Cemiplimab therapy for adult cutaneous squamous cell carcinoma (SCC) in the metastatic setting.
This survey is intended to gather patient perspective to inform the Save Your Skin Foundation treatment recommendations to the CADTH Common Drug Review (CDR) and to pan-Canadian Oncology Drug Review (pCODR).
We invite all cutaneous squamous cell carcinoma patients who received Libtayo/Cemiplimab to complete this survey by July 17, 2019.
This survey is now closed, thank you to all who shared their experience.
Thank you!
